Speaker Profile
M.D., Ph.D., Vice President, Real World Evidence, Guardant Health
Biography
Dr. Amar Das has three decades of experience in advancing clinical researchthrough data science and AI. At Guardant Health, he leads a team thatgenerates real world evidence for blood-based testing in precision oncologyand cancer screening. Prior to Guardant Health, Dr. Das was on the facultyat Stanford and Dartmouth. As Director of Biomedical Informatics at Dartmouth, he co-founded the Department of Biomedical Data Science, thefirst department focused on this discipline. Following his career inacademia, he served as Director of Healthcare Effectiveness Research at IB Mand Director of Real World Data Analytics and Innovation at MerckMSD. Dr. Das has received multiple professional and research awards, and is a Fellowof the American College of Medical Informatics. Dr. Das received his MD and PhD in Biomedical Informatics from Stanford and completed his residency andpostdoctoral fellowship in Clinical Epidemiology at Columbia New York Presbyterian.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Adrian Lee, UPMC
PMWC Award Ceremony
• Dennis J. Slamon, UCLA
• Arul M. Chinnaiyan, University of Michigan
Keynote: Molecular Diversity of Human Malignancies: Diagnostic and Therapeutic Implications
• Dennis J. Slamon, UCLA
Keynote: From Cancer Drivers to Clinical Decisions: Transforming Tumor Genomics
• Arul M. Chinnaiyan, University of Michigan
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Adrian Lee, UPMC
• Pedram Razavi, MSK
• Minetta Liu, Natera
• Emre Baser, Astrazeneca
• Christian Rolfo, Ohio State
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, UPenn
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
• C. Ola Landgren, U Miami
• Christopher Lieu, U Colorado
Rapid MRD to Treatment Decisions: Standardized ctDNA at Scale
• Chair: Luca Quagliata, Thermo Fisher
• Christian Rolfo, Ohio State
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• Chair: David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
• Daniel De Carvalho, University of Toronto
From Detection to Direction: Whole-Genome MRD for Therapy Guidance at Scale
• Phil Febbo, Veracyte
Precision Engineering: Customizing High-Sensitivity ctDNA Assays for Therapy Guidance at Scale
• Siyuan Chen, Twist Bioscience
From Validation to Payment: Coverage Pathways That Work
• Chair: Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society (ACS)
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
